tiprankstipranks
Abbott Laboratories (GB:0Q15)
LSE:0Q15
UK Market
0Q15
Abbott Laboratories
RESEARCH TOOLSreports

Abbott Laboratories (0Q15) Share Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

0Q15 Analyst Ratings

Strong Buy
15Ratings
Strong Buy
15 Buy
0 Hold
0 Sell
Based on 15 analysts giving stock ratings to
Abbott
Laboratories
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0Q15 Stock 12 Month Forecast

Average Price Target

$124.33
▲(12.04% Upside)
Based on 15 Wall Street analysts offering 12 month price targets for Abbott Laboratories in the last 3 months. The average price target is $124.33 with a high forecast of $135.00 and a low forecast of $112.00. The average price target represents a 12.04% change from the last price of $110.97.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"86":"$86","111":"$111","136":"$136","98.5":"$98.5","123.5":"$123.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":135,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$135.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":124.33333333333333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$124.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":112,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$112.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[86,98.5,111,123.5,136],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,109.54,111.49846153846154,113.45692307692308,115.41538461538462,117.37384615384616,119.3323076923077,121.29076923076923,123.24923076923078,125.20769230769231,127.16615384615385,129.1246153846154,131.08307692307693,133.04153846153847,{"y":135,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,109.54,110.67794871794872,111.81589743589744,112.95384615384616,114.09179487179487,115.22974358974359,116.36769230769231,117.50564102564103,118.64358974358974,119.78153846153846,120.91948717948718,122.0574358974359,123.19538461538461,{"y":124.33333333333333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,109.54,109.72923076923078,109.91846153846154,110.10769230769232,110.29692307692308,110.48615384615385,110.67538461538462,110.86461538461539,111.05384615384615,111.24307692307693,111.43230769230769,111.62153846153846,111.81076923076922,{"y":112,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":129.266,"date":1756674000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.768,"date":1759266000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.721,"date":1761948000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":126.735,"date":1764540000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.539,"date":1767218400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.578,"date":1769896800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.184,"date":1772316000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.101,"date":1774990800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.159,"date":1777582800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.004,"date":1780261200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.413,"date":1782853200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.74,"date":1785531600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.54,"date":1788210000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$135.00Average Price Target$124.33Lowest Price Target$112.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on GB:0Q15
Robbie Marcus
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
09/01/26
Analysts Offer Insights on Healthcare Companies: PMV Pharmaceuticals (NASDAQ: PMVP), Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Abbott Laboratories (NYSE: ABT)
TD Cowen Analyst forecast on GB:0Q15
Josh Jennings
TD Cowen
TD Cowen
$135
Buy
21.65%
Upside
Reiterated
08/31/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Abbott Laboratories (NYSE: ABT), PTC Therapeutics (NASDAQ: PTCT) and Ansell (Other OTC: ANSLF)
Wells Fargo Analyst forecast on GB:0Q15
Larry Biegelsen
Wells Fargo
Wells Fargo
$112
Buy
0.93%
Upside
Reiterated
08/27/26
Wells Fargo Keeps Their Buy Rating on Abbott Laboratories (ABT)
Piper Sandler Analyst forecast on GB:0Q15
Adam Maeder
Piper Sandler
Piper Sandler
$118
Buy
6.34%
Upside
Reiterated
08/26/26
Piper Sandler Sticks to Their Buy Rating for Abbott Laboratories (ABT)
Jefferies Analyst forecast on GB:0Q15
Matthew Taylor
Jefferies
Jefferies
$135
Buy
21.65%
Upside
Reiterated
08/21/26
Jefferies Sticks to Their Buy Rating for Abbott Laboratories (ABT)
William Blair Analyst forecast on GB:0Q15
Brandon Vazquez
William Blair
William Blair
―
Buy
―
Reiterated
08/21/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Abbott Laboratories (NYSE: ABT) and Doximity (NYSE: DOCS)
Bank of America Securities Analyst forecast on GB:0Q15
Travis Steed
Bank of America Securities
Bank of America Securities
$115
Buy
3.63%
Upside
Reiterated
08/20/26
Analysts Offer Insights on Healthcare Companies: Savara (NASDAQ: SVRA), AptarGroup (NYSE: ATR) and Abbott Laboratories (NYSE: ABT)
BTIG Analyst forecast on GB:0Q15
Marie Thibault
BTIG
BTIG
$134
Buy
20.75%
Upside
Reiterated
08/20/26
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (NASDAQ: CORT), Alvotech (NASDAQ: ALVO) and Abbott Laboratories (NYSE: ABT)
Citi Analyst forecast on GB:0Q15
Joanne Wuensch
Citi
Citi
$112→$125
Buy
12.64%
Upside
Reiterated
08/14/26
Abbott Laboratories (ABT) Receives a Buy from Citi
Wolfe Research Analyst forecast on GB:0Q15
Michael Polark
Wolfe Research
Wolfe Research
$130
Buy
17.15%
Upside
Upgraded
08/13/26
Analysts' Top Healthcare Picks: Liquidia Technologies (LQDA), Abbott Laboratories (ABT)
UBS Analyst forecast on GB:0Q15
Patrick Wood
UBS
UBS
$135→$125
Buy
12.64%
Upside
Assigned
07/28/26
UBS Issues a Buy Rating on Abbott Laboratories (ABT)
Raymond James Analyst forecast on GB:0Q15
Jayson Bedford
Raymond James
Raymond James
―
Buy
―
Reiterated
07/17/26
Abbott Laboratories (ABT) Gets a Buy from Raymond James
RBC Capital Analyst forecast on GB:0Q15
Shagun Singh Chadha
RBC Capital
RBC Capital
$130
Buy
17.15%
Upside
Reiterated
07/16/26
RBC Capital Sticks to Their Buy Rating for Abbott Laboratories (ABT)
Evercore ISI Analyst forecast on GB:0Q15
Vijay Kumar
Evercore ISI
Evercore ISI
$120→$112
Buy
0.93%
Upside
Reiterated
07/06/26
Abbott price target lowered to $112 from $120 at Evercore ISIAbbott price target lowered to $112 from $120 at Evercore ISI
Robert W. Baird Analyst forecast on GB:0Q15
David Rescott
Robert W. Baird
Robert W. Baird
$121
Buy
9.04%
Upside
Initiated
06/30/26
Abbott initiated with an Outperform at BairdAbbott initiated with an Outperform at Baird
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on GB:0Q15
Robbie Marcus
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
09/01/26
Analysts Offer Insights on Healthcare Companies: PMV Pharmaceuticals (NASDAQ: PMVP), Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Abbott Laboratories (NYSE: ABT)
TD Cowen Analyst forecast on GB:0Q15
Josh Jennings
TD Cowen
TD Cowen
$135
Buy
21.65%
Upside
Reiterated
08/31/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Abbott Laboratories (NYSE: ABT), PTC Therapeutics (NASDAQ: PTCT) and Ansell (Other OTC: ANSLF)
Wells Fargo Analyst forecast on GB:0Q15
Larry Biegelsen
Wells Fargo
Wells Fargo
$112
Buy
0.93%
Upside
Reiterated
08/27/26
Wells Fargo Keeps Their Buy Rating on Abbott Laboratories (ABT)
Piper Sandler Analyst forecast on GB:0Q15
Adam Maeder
Piper Sandler
Piper Sandler
$118
Buy
6.34%
Upside
Reiterated
08/26/26
Piper Sandler Sticks to Their Buy Rating for Abbott Laboratories (ABT)
Jefferies Analyst forecast on GB:0Q15
Matthew Taylor
Jefferies
Jefferies
$135
Buy
21.65%
Upside
Reiterated
08/21/26
Jefferies Sticks to Their Buy Rating for Abbott Laboratories (ABT)
William Blair Analyst forecast on GB:0Q15
Brandon Vazquez
William Blair
William Blair
―
Buy
―
Reiterated
08/21/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Abbott Laboratories (NYSE: ABT) and Doximity (NYSE: DOCS)
Bank of America Securities Analyst forecast on GB:0Q15
Travis Steed
Bank of America Securities
Bank of America Securities
$115
Buy
3.63%
Upside
Reiterated
08/20/26
Analysts Offer Insights on Healthcare Companies: Savara (NASDAQ: SVRA), AptarGroup (NYSE: ATR) and Abbott Laboratories (NYSE: ABT)
BTIG Analyst forecast on GB:0Q15
Marie Thibault
BTIG
BTIG
$134
Buy
20.75%
Upside
Reiterated
08/20/26
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (NASDAQ: CORT), Alvotech (NASDAQ: ALVO) and Abbott Laboratories (NYSE: ABT)
Citi Analyst forecast on GB:0Q15
Joanne Wuensch
Citi
Citi
$112→$125
Buy
12.64%
Upside
Reiterated
08/14/26
Abbott Laboratories (ABT) Receives a Buy from Citi
Wolfe Research Analyst forecast on GB:0Q15
Michael Polark
Wolfe Research
Wolfe Research
$130
Buy
17.15%
Upside
Upgraded
08/13/26
Analysts' Top Healthcare Picks: Liquidia Technologies (LQDA), Abbott Laboratories (ABT)
UBS Analyst forecast on GB:0Q15
Patrick Wood
UBS
UBS
$135→$125
Buy
12.64%
Upside
Assigned
07/28/26
UBS Issues a Buy Rating on Abbott Laboratories (ABT)
Raymond James Analyst forecast on GB:0Q15
Jayson Bedford
Raymond James
Raymond James
―
Buy
―
Reiterated
07/17/26
Abbott Laboratories (ABT) Gets a Buy from Raymond James
RBC Capital Analyst forecast on GB:0Q15
Shagun Singh Chadha
RBC Capital
RBC Capital
$130
Buy
17.15%
Upside
Reiterated
07/16/26
RBC Capital Sticks to Their Buy Rating for Abbott Laboratories (ABT)
Evercore ISI Analyst forecast on GB:0Q15
Vijay Kumar
Evercore ISI
Evercore ISI
$120→$112
Buy
0.93%
Upside
Reiterated
07/06/26
Abbott price target lowered to $112 from $120 at Evercore ISIAbbott price target lowered to $112 from $120 at Evercore ISI
Robert W. Baird Analyst forecast on GB:0Q15
David Rescott
Robert W. Baird
Robert W. Baird
$121
Buy
9.04%
Upside
Initiated
06/30/26
Abbott initiated with an Outperform at BairdAbbott initiated with an Outperform at Baird
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
PTGXProtagonist Therapeutics
AXGNAxoGen
ATECAlphatec Holdings
CABACabaletta Bio
ONCBeOne Medicines
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Abbott Laboratories

3 Months
Matthew TaylorJefferies
Success Rate
17/23 ratings generated profit
74%
Average Return
+3.14%
Copying Matthew Taylor's trades and holding each position for 3 Months would result in 73.91% of your transactions generating a profit, with an average return of +3.14% per trade.
1 Year
Jayson BedfordRaymond James
Success Rate
35/44 ratings generated profit
80%
Average Return
+15.95%
Copying Jayson Bedford's trades and holding each position for 1 Year would result in 79.55% of your transactions generating a profit, with an average return of +15.95% per trade.
2 Years
Matthew TaylorJefferies
Success Rate
17/23 ratings generated profit
74%
Average Return
+27.98%
Copying Matthew Taylor's trades and holding each position for 2 Years would result in 73.91% of your transactions generating a profit, with an average return of +27.98% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0Q15 Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
0
0
0
0
0
Buy
33
38
33
42
32
Hold
6
5
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
39
43
33
42
32
In the current month, 0Q15 has received 32 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 0Q15 average Analyst price target in the past 3 months is 124.33.
Each month's total comprises the sum of three months' worth of ratings.

0Q15 Financial Forecast

0Q15 Earnings Forecast

Next quarter’s earnings estimate for 0Q15 is $1.42 with a range of $1.40 to $1.44. The previous quarter’s EPS was $1.31. 0Q15 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0Q15 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0Q15 is $1.42 with a range of $1.40 to $1.44. The previous quarter’s EPS was $1.31. 0Q15 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0Q15 has Performed in-line its overall industry.

0Q15 Sales Forecast

Next quarter’s sales forecast for 0Q15 is $12.99B with a range of $12.90B to $13.16B. The previous quarter’s sales results were $12.59B. 0Q15 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0Q15 has Performed in-line its overall industry.
Next quarter’s sales forecast for 0Q15 is $12.99B with a range of $12.90B to $13.16B. The previous quarter’s sales results were $12.59B. 0Q15 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0Q15 has Performed in-line its overall industry.

0Q15 Stock Forecast FAQ

What is GB:0Q15’s average 12-month price target, according to analysts?
Based on analyst ratings, Abbott Laboratories’s 12-month average price target is 124.33.
    What is GB:0Q15’s upside potential, based on the analysts’ average price target?
    Abbott Laboratories has 12.04% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Abbott Laboratories a Buy, Sell or Hold?
          Abbott Laboratories has a consensus rating of Strong Buy, which is based on 15 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Abbott Laboratories’s share price target?
            The average share price target for Abbott Laboratories is 124.33. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $135.00 ,and the lowest forecast is $112.00. The average share price target represents 12.04% Increase from the current price of $110.97.
              What do analysts say about Abbott Laboratories?
              Abbott Laboratories’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.
                How can I buy shares of Abbott Laboratories?
                To buy shares of GB:0Q15, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.